🇺🇸 FDA
Pipeline program

Vedolizumab

TAK01769

Approved mab active

Quick answer

Vedolizumab for Moderately to Severely Active Crohn's Disease is a Approved program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Moderately to Severely Active Crohn's Disease
Phase
Approved
Modality
mab
Status
active

Clinical trials